GEHC logo

GE HealthCare

GEHC · What the business does, what can go wrong, and how options sellers approach it

What it does

GE HealthCare Technologies makes the machines and software hospitals use to see inside the body and monitor patients. Its products include MRI, CT, X-ray, PET and ultrasound systems, plus patient monitoring and care equipment. It also sells contrast agents and radiopharmaceuticals, which are the substances injected into patients to make scans clearer.

The company was spun out of General Electric and trades independently.

How it makes money

Revenue comes from several streams:

  • Equipment sales: hospitals, clinics and imaging centers buy scanners and monitors.
  • Service: long-term contracts to maintain and repair installed machines, which tend to be steadier than equipment orders.
  • Pharmaceutical diagnostics: contrast media and imaging agents used in procedures, which are recurring consumables.
  • Digital and software: tools for imaging workflow, analytics and device connectivity.

Why investors own it

Many investors see a large installed base of equipment that generates ongoing service and consumables revenue. Healthcare demand tends to be less tied to the economic cycle than many industries. An aging population and the push for earlier, more accurate diagnosis support long-term imaging use. Some also point to the potential for software and AI-assisted tools to add value on top of the hardware.

What can go wrong

  • Hospital budgets can tighten, delaying big equipment purchases.
  • Competition from other large imaging makers can pressure prices.
  • Sales outside the U.S., including China, expose the company to tariffs, trade policy, currency swings and local procurement rules.
  • Complex global supply chains can be disrupted or become more costly.
  • Medical devices face regulatory scrutiny, and recalls or approval delays can hurt results.

What to watch

  • Order growth and backlog
  • Organic revenue growth by segment
  • Service and recurring revenue mix
  • Operating margin trends
  • Free cash flow conversion
  • Pharmaceutical diagnostics volumes
  • Tariff and trade policy developments
  • Regulatory approvals for new products

Options income angle

Options on GEHC are generally available across several expirations and are typically reasonably liquid, though usually less active than those on the largest mega-cap names. Bid-ask spreads can be wider on strikes far from the current price.

Implied volatility tends to rise ahead of quarterly earnings, and also around guidance changes, tariff news and shifts in healthcare spending expectations.

One caution for premium sellers: an earnings report can cause a sharp price gap, and a short option can lose far more than the premium collected. Check the earnings date before choosing an expiration.

What the latest 10-K says

A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 4, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The filing in brief

GE HealthCare grew Total revenues to $20,625 million in 2025, up 4.8%, and Operating income rose to $2,763 million. Tariffs cut Operating income by approximately $245 million and cash flows by approximately $285 million, and management does not expect its mitigation actions to fully offset them. Debt rose to $10,003 million ahead of a planned $2,300 million acquisition.

How the business did

  • Total revenues grew 4.8% as reported and 3.5% organically (organic leaves out acquisitions, dispositions and currency swings). Net income attributable to GE HealthCare was $2,084 million, up from $1,993 million.
  • Pharmaceutical Diagnostics (PDx) revenues were $2,900 million, up 15.6%, helped by the Nihon Medi-Physics (NMP) acquisition. Patient Care Solutions revenues were $3,086 million, down 1.2%, and its Segment EBIT fell to $209 million, a decrease of $137 million.
  • Profit did not keep pace with sales. Gross profit as a share of revenue fell 170 basis points (a basis point is one hundredth of a percentage point), driven by cost inflation including tariffs. Adjusted EBIT, a non-GAAP measure (one that strips out items management considers non-operating), was $3,155 million, down 1.8%.
  • China region revenues were $2,251 million, down 4.6%.
  • Cash from operating activities was $1,987 million. Free cash flow was $1,505 million versus $1,554 million. The company repurchased common stock for total consideration of $200 million.

Risks specific to this company

  • Tariffs: The U.S. and other countries imposed new tariffs during 2025. Management says that if they continue at formally communicated levels, a material impact on results should continue.
  • China: Local competition and Volume Based Procurement policies have hurt orders and revenues. A healthcare anti-corruption campaign begun in 2023 delayed orders and sales, and some Chinese court judgments name the company's products, employees and channel partners.
  • Supply chain: The company has multiple single-source or sole-source suppliers with no alternatives identified. China tightened rare earth export controls in 2025, and only some of the restrictions were temporarily suspended in October 2025.
  • Debt: Borrowings stood at $10,003 million, and the debt agreements carry covenants. A substantial portion of cash is held overseas, while the debt is primarily held in the U.S.
  • Pensions: Total postretirement plans show a funded status of $(4,365) million, meaning obligations exceed assets. A 1% change in the assumed return on plan assets would move 2026 net periodic benefit costs by $188 million.
  • Russia: Customers in Russia and Ukraine generated revenues of $353 million. Export licensing requirements affected supply to Russian customers and are expected to keep doing so.

What management is watching

  • Acquisition and financing: On November 20, 2025, the company announced an agreement to acquire Intelerad for $2,300 million in cash. It entered a Delayed Draw Term Loan Facility of $750 million as part of the funding.
  • Trade: Management is monitoring tariffs, China purchasing decisions, and whether negative sentiment toward U.S. companies affects global customers.
  • Investment: Additions to PP&E and internal-use software were $482 million, mostly for manufacturing capacity expansion and new product introductions. Engineering costs for design follow-through on new products were $490 million, versus $405 million the prior year.
  • Seasonality: Fourth-quarter results have historically been higher than other quarters because of customer spending patterns.
  • Measures management points to: Organic revenue, Adjusted EBIT, Adjusted earnings per share (reported at $4.59) and Free cash flow.

What the latest 10-Q says

A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 28, 2026. Figures are as the filing reports them. Read the filing on SEC.gov

The quarter in brief

GE HealthCare reported third-quarter revenues of $5,513 million, up 7.2%, and operating income of $805 million, up from $653 million a year earlier. Higher volume, higher prices and smaller tariff costs drove the gain. Tariffs, however, remain a material cost, and the company says its mitigation efforts will not fully offset them.

How the business did

  • Quarter: Revenues grew 7.2% as reported and 6.2% organically (organic strips out acquisitions, disposals and currency swings). Net income attributable to the company was $615 million versus $446 million. A lower tax bill helped: the effective tax rate was 17.1% versus 27.8%, partly from foreign income tax reserve releases.
  • Year to date: Nine-month revenues were $15,939 million, up 6.8% (4.2% organic). Operating income was $2,058 million versus $1,936 million, and net income attributable was $1,564 million versus $1,495 million.
  • Segments: Following a second-quarter reorganization, Imaging and Advanced Visualization Solutions were combined into Advanced Imaging Solutions (AIS), with revenues of $3,873 million. Pharmaceutical Diagnostics revenues were $846 million, up 13.0%, on contrast media and radiopharmaceutical volume and price. Patient Care Solutions revenues were $793 million, up 8.5%, but nine-month revenues of $2,171 million were down 4.0% on operational and fulfillment challenges.
  • Cash and capital: Nine-month operating cash flow was $1,365 million versus $937 million, and free cash flow was $973 million versus $589 million. The company spent $2,293 million (net of cash acquired) buying Intelerad and $300 million repurchasing stock. Total debt was $9,973 million.
  • Unusual items: The company recognized pre-tax benefits from IEEPA tariff refunds of $115 million for the nine months on 2025 tariffs. The Supreme Court ruled in February 2026 that the act does not authorize those tariffs.

What management is watching

  • Tariffs: Direct tariffs reduced operating income by $53 million in the quarter and $209 million for the nine months. The company plans more refund claims, but timing and amounts are uncertain.
  • Costs and supply: Middle East conflict raised costs and strained supply chains and logistics. Management also tracks memory chips, freight and oil-linked costs. In China, local competitors and volume-based procurement policies have hurt orders and revenues and may continue to.
  • Spending: Additions to property, plant and equipment and internal-use software were $392 million for the nine months, mostly facilities, manufacturing capacity expansion and new products. Engineering costs tied to new product launches and upkeep were $141 million in the quarter.
  • Measures management points to: Organic revenue, Adjusted EBIT (operating profit with one-time and non-cash items removed) and free cash flow (operating cash flow minus capital spending). Third-quarter Adjusted EBIT was $913 million, a 16.6% margin.

Follow GEHC in Kortex

The Kortex app shows GEHC's price, options chain and IV rank, and answers your questions from live market data and SEC filings.

Free to download.

Learn the strategies

More stock briefs

For education only, not financial advice. Options involve risk and are not suitable for every investor.